Literature DB >> 10934137

Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms.

M Ladanyi1.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10934137      PMCID： PMC1850118          DOI： 10.1016/S0002-9440(10)64545-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  60 in total

Review 1.  The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma.

Authors:  M Ladanyi
Journal:  Cancer Surv       Date:  1997

2.  A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma.

Authors:  S R Knezevich; D E McFadden; W Tao; J F Lim; P H Sorensen
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

Review 3.  Gastrointestinal stromal tumors: recent advances in understanding of their biology.

Authors:  M Miettinen; M Sarlomo-Rikala; J Lasota
Journal:  Hum Pathol       Date:  1999-10       Impact factor: 3.466

4.  Lymphomas expressing ALK fusion protein(s) other than NPM-ALK.

Authors:  B Falini; K Pulford; A Pucciarini; A Carbone; C De Wolf-Peeters; J Cordell; M Fizzotti; A Santucci; P G Pelicci; S Pileri; E Campo; G Ott; G Delsol; D Y Mason
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

Review 5.  HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors.

Authors:  G Tallini; P Dal Cin
Journal:  Adv Anat Pathol       Date:  1999-09       Impact factor: 3.875

6.  Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation.

Authors:  D Y Mason; K A Pulford; D Bischof; M U Kuefer; L H Butler; L Lamant; G Delsol; S W Morris
Journal:  Cancer Res       Date:  1998-03-01       Impact factor: 12.701

7.  An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation.

Authors:  H Ichikawa; K Shimizu; Y Hayashi; M Ohki
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

8.  Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases.

Authors:  C M Coffin; J Watterson; J R Priest; L P Dehner
Journal:  Am J Surg Pathol       Date:  1995-08       Impact factor: 6.394

9.  Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity.

Authors:  M Shiota; S Nakamura; R Ichinohasama; M Abe; T Akagi; M Takeshita; N Mori; J Fujimoto; J Miyauchi; A Mikata; K Nanba; T Takami; H Yamabe; Y Takano; T Izumo; T Nagatani; N Mohri; K Nasu; H Satoh; H Katano; J Fujimoto; T Yamamoto; S Mori
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

10.  Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22).

Authors:  I Panagopoulos; P Aman; T Fioretos; M Höglund; B Johansson; N Mandahl; S Heim; M Behrendtz; F Mitelman
Journal:  Genes Chromosomes Cancer       Date:  1994-12       Impact factor: 5.006
View more
  6 in total

1.  The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.

Authors:  B Maes; V Vanhentenrijk; I Wlodarska; J Cools; B Peeters; P Marynen; C de Wolf-Peeters
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Authors:  James E Butrynski; David R D'Adamo; Jason L Hornick; Paola Dal Cin; Cristina R Antonescu; Suresh C Jhanwar; Marc Ladanyi; Marzia Capelletti; Scott J Rodig; Nikhil Ramaiya; Eunice L Kwak; Jeffrey W Clark; Keith D Wilner; James G Christensen; Pasi A Jänne; Robert G Maki; George D Demetri; Geoffrey I Shapiro
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.

Authors:  G Z Rassidakis; A H Sarris; M Herling; R J Ford; F Cabanillas; T J McDonnell; L J Medeiros
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

4.  Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer.

Authors:  Ferdous-Rastgar Jazii; Zahra Najafi; Reza Malekzadeh; Thomas-P Conrads; Abed-Ali Ziaee; Christian Abnet; Mansour Yazdznbod; Ali-Asghar Karkhane; Ghasem-H Salekdeh
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

5.  Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.

Authors:  Artur Slupianek; Grazyna Hoser; Ireneusz Majsterek; Agnieszka Bronisz; Maciej Malecki; Janusz Blasiak; Richard Fishel; Tomasz Skorski
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

Review 6.  Emerging therapeutic targets for soft tissue sarcoma.

Authors:  Jason L Smith; Richard F Riedel
Journal:  Curr Oncol Rep       Date:  2011-08       Impact factor: 5.075
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.